These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 28091366)

  • 1. Trastuzumab emtansine and cost-based decision making.
    The Lancet
    Lancet; 2017 Jan; 389(10064):2. PubMed ID: 28091366
    [No Abstract]   [Full Text] [Related]  

  • 2. NICE approves trastuzumab emtansine after deal with drug company.
    Kmietowicz Z
    BMJ; 2017 Jun; 357():j2930. PubMed ID: 28623237
    [No Abstract]   [Full Text] [Related]  

  • 3. NICE says drug for metastatic breast cancer is unaffordable for NHS.
    Kmietowicz Z
    BMJ; 2014 Apr; 348():g2888. PubMed ID: 24759923
    [No Abstract]   [Full Text] [Related]  

  • 4. NICE rejects trastuzumab emtansine for use on NHS.
    Kmietowicz Z
    BMJ; 2015 Dec; 351():h6837. PubMed ID: 26673454
    [No Abstract]   [Full Text] [Related]  

  • 5. NICE, the NHS, and Cancer Drugs.
    Dillon A; Landells LJ
    JAMA; 2018 Feb; 319(8):767-768. PubMed ID: 29387883
    [No Abstract]   [Full Text] [Related]  

  • 6. Time for a level playing field: inequalities in regulatory/approval processes—the example of bevacizumab in epithelial ovarian cancer.
    Hoskins PJ; Fung-Kee-Fung M; Miller D; Gotlieb W
    J Clin Oncol; 2015 May; 33(14):1539-42. PubMed ID: 25847922
    [No Abstract]   [Full Text] [Related]  

  • 7. British clinic is allowed to deny medicine; decision on cost has broad impact.
    Lyall S
    N Y Times Web; 2006 Feb; ():A10. PubMed ID: 16514743
    [No Abstract]   [Full Text] [Related]  

  • 8. NICE recommends routine NHS funding for Kadcyla.
    Venkatesa P
    Lancet Oncol; 2017 Aug; 18(8):e435. PubMed ID: 28648556
    [No Abstract]   [Full Text] [Related]  

  • 9. Breast Cancer Advocacy Coalition responds to the 'Herceptin or deception' article.
    ; Burgess EP
    N Z Med J; 2006 Jul; 119(1237):U2065; author reply U2065. PubMed ID: 16862207
    [No Abstract]   [Full Text] [Related]  

  • 10. Trastuzumab for early breast cancer: evolution or revolution?
    Littlejohns P
    Lancet Oncol; 2006 Jan; 7(1):22-3. PubMed ID: 16408378
    [No Abstract]   [Full Text] [Related]  

  • 11. An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab case.
    Ades F; Senterre C; Zardavas D; de Azambuja E; Popescu R; Parent F; Piccart M
    Eur J Cancer; 2014 Dec; 50(18):3089-97. PubMed ID: 25446375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oh, Canada: Public outcry pushed demand for trastuzumab for early-stage breast cancer.
    Smith M
    J Natl Cancer Inst; 2005 Sep; 97(18):1327. PubMed ID: 16174852
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer.
    Reed SD; Schulman KA
    Value Health; 2009; 12(5):637-40. PubMed ID: 19473336
    [No Abstract]   [Full Text] [Related]  

  • 14. Report blames NICE for hastening decline of UK biotech.
    Moran N
    Nat Biotechnol; 2009 Mar; 27(3):215-7. PubMed ID: 19270658
    [No Abstract]   [Full Text] [Related]  

  • 15. [Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers].
    Guerin M; Sabatier R; Gonçalves A
    Bull Cancer; 2015 Apr; 102(4):390-7. PubMed ID: 25790739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How much will Herceptin really cost?
    Barrett A; Roques T; Small M; Smith RD
    BMJ; 2006 Nov; 333(7578):1118-20. PubMed ID: 17124225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.
    Danese MD; Masaquel A; Santos E; Brammer M; Lee A; Lalla D
    Value Health; 2015 Sep; 18(6):876-83. PubMed ID: 26409616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Watchdog set to reject four drugs for kidney cancer on the NHS.
    O'Dowd A
    BMJ; 2008 Aug; 337():a1262. PubMed ID: 18703648
    [No Abstract]   [Full Text] [Related]  

  • 19. Patient priority in the era of patent expiries.
    The Lancet Oncology
    Lancet Oncol; 2014 Sep; 15(10):1039. PubMed ID: 25186040
    [No Abstract]   [Full Text] [Related]  

  • 20. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
    Med Lett Drugs Ther; 2013 Sep; 55(1425):75-6. PubMed ID: 24662957
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.